ANI Pharmaceuticals (ANIP) CEO sells 5,400 shares under trading plan

Rhea-AI Filing Summary

ANI PHARMACEUTICALS INC (ANIP) reported that President & CEO Nikhil Lalwani sold 5,400 shares of common stock on August 25, 2026 in an open-market or private transaction at a weighted average price of $74.30 per share, with trades ranging from $73.58 to $74.61. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 26, 2026. Following this sale, Lalwani directly holds 344,489 shares of ANIP common stock.

Insider Trade Summary 10b5-1

Net Seller: 5,400 shares

Net Sell 1 txn

Insider Lalwani Nikhil

Role PRESIDENT & CEO

Sold 5,400 shs ($401K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	5,400	$74.30	$401K

Holdings After Transaction: Common Stock — 344,489 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.
2. F2. The shares were sold in multiple trades at prices ranging from $73.58 to $74.61. The price reported above reflects the weighted average sales price.

Key Figures

Shares sold: 5,400 shares of Common Stock Weighted average sales price: $74.30 per share Approximate transaction value: $401,220 +2 more

5 metrics

Shares sold 5,400 shares of Common Stock Non-derivative sale on August 25, 2026

Weighted average sales price $74.30 per share Common Stock sale on August 25, 2026; trades ranged $73.58–$74.61

Approximate transaction value $401,220 5,400 shares sold at a weighted average price of $74.30 per share

Shares held after transaction 344,489 shares Direct ownership by CEO Nikhil Lalwani following August 25, 2026 sale

Net shares sold in filing 5,400 shares transactionSummary netBuySellShares for this Form 4

Key Terms

Rule 10b5-1 trading plan, weighted average sales price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price financial

"The price reported above reflects the weighted average sales price"

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

FAQ

What insider transaction did ANIP report for CEO Nikhil Lalwani on this Form 4?

ANI PHARMACEUTICALS INC reported that CEO Nikhil Lalwani sold 5,400 shares of common stock on August 25, 2026 in a sale coded as an open-market or private transaction.

At what price did the ANIP shares sell in Nikhil Lalwani’s reported transaction?

The reported transaction shows a weighted average sales price of $74.30 per share, with individual trades executed at prices ranging from $73.58 to $74.61.

How many ANIP shares does CEO Nikhil Lalwani hold after the reported sale?

After the August 25, 2026 sale, CEO Nikhil Lalwani directly holds 344,489 shares of ANI PHARMACEUTICALS INC common stock.

Was the ANIP insider sale by Nikhil Lalwani made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Nikhil Lalwani on May 26, 2026.

How many total shares did ANIP’s CEO sell in this Form 4 filing?

The Form 4 reports that CEO Nikhil Lalwani sold a total of 5,400 shares of ANI PHARMACEUTICALS INC common stock in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 06:15 PM Accepted by SEC EDGAR 08/26/2026 - 06:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalwani Nikhil

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2026		S(1)		5,400	D	$74.3(2)	344,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.

2. The shares were sold in multiple trades at prices ranging from $73.58 to $74.61. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)